Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings

Mar 20

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.

Analysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.

On Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.

Shares of Milestone Pharmaceuticals closed at $1.70 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

HC Wainwright & Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.
Wells Fargo analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.
TD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.

Considering buying MIST stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2620200509"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620200509\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620200509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 14:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620200509","market":"us","top_or_hot":-1,"title":"Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a></strong> (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.</p>\n<p>Analysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.</p>\n<p>On Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.</p>\n<p>Shares of Milestone Pharmaceuticals closed at $1.70 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.</li>\n<li>TD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.</li>\n</ul>\n<p>Considering buying MIST stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"519\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-768x389.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445.png 1213w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMilestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-03-20 14:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a></strong> (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.</p>\n<p>Analysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.</p>\n<p>On Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.</p>\n<p>Shares of Milestone Pharmaceuticals closed at $1.70 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.</li>\n<li>TD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.</li>\n</ul>\n<p>Considering buying MIST stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"519\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-768x389.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445.png 1213w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372442/milestone-pharmaceuticals-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts","article_id":"2620200509","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620200509","pubTimestamp":1773987785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIST":"Milestone Pharmaceuticals Inc."},"translate_title":"Milestone Pharmaceuticals准备第四季度印刷；以下是华尔街最准确的分析师最近的预测变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIST":1},"content_text":"Milestone Pharmaceuticals Inc. (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.\nAnalysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.\nOn Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.\nShares of Milestone Pharmaceuticals closed at $1.70 on Thursday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nHC Wainwright & Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.\nWells Fargo analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.\nTD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.\n\nConsidering buying MIST stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}